Effect of the Knockout of FGL1 by CRISPR on the GefitinibSensitivity of PC9/GR Cells

Abstract

This paper will investigate the effect of the Knockout of FGL1 by CRISPR on the EGFR signaling analyzed phosphor
ERK western blot and how it may control the gefitinib sensitivity of PC9/GR cells measured by the MTT Assay. This
experiment will knock out FGL1 using CRISPR. The Knockout will then be verified through Phospho-ERK western
blot. Moreover, the sensitivity of the gefitinib will be measured by the MTT Assay. The possible results generated from
the reports’ experiments may provide insight into future clinical trials of FGL1 Knockout consequences on gefitinib
sensitivity. Gefitinib is a potential drug for lung cancer. Therefore, investigating this drug may help scientists better
understand how the FGL1 may increase the sensitivity of Gefitinib cells and potentially discover a breakthrough to cure
cancer.